



Date: 2 October 2018

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

**Registered Office
and**

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

**Board of Directors
Mr Peter Marks**

Chairman
Non-Executive
Director

Dr Graham Kelly
Chief Executive Officer
Managing Director

Dr Ian Dixon
Non-Executive
Director

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT 2001 (CTH)

For the purposes of section 708A(5)(e) of the Corporations Act 2001 (Cth), Noxopharm Limited (ASX: NOX) (**Noxopharm** or the **Company**) hereby provides notice that today it has issued 50,000 new fully paid ordinary shares, from the exercise of unlisted options, at an exercise price of \$0.30 per share, with an expiry date of 28 February 2021 (**New Shares**). The New Shares will rank equally in respects with existing ordinary shares.

Please see attached Appendix 3B for more details.

NOX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The New Shares and Options were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NOX has complied with:
 - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NOX; and
 - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

A handwritten signature in blue ink, appearing to read "D. Franks", with a horizontal line underneath.

David Franks
Company Secretary